Reduction of factor FVIIa activity during heparin therapy evidence for assay interactions with tissue factor pathway inhibitor and antithrombin

Thrombosis Research

Volumn 100, Issue 5, 2000, Pages 389-396

  Hansen, John Bjarne ^a   Svensson, Birgit ^a   Sandset, Per Morten ^b   Thijssen, Frances ^b  

^a UNIVERSITY OF TROMSØ   (Norway)

^b UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Antithrombin; Factor VIIa; Heparin; TFPI

Indexed keywords

ANTITHROMBIN; BLOOD CLOTTING FACTOR 8A; HEPARIN; HEXADIMETHRINE BROMIDE; TISSUE FACTOR PATHWAY INHIBITOR;

ADULT; ANTICOAGULANT THERAPY; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; BLOOD CLOTTING TEST; BOLUS INJECTION; CONTINUOUS INFUSION; HEPARINIZATION; HUMAN; HUMAN EXPERIMENT; INFUSION PUMP; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

ADULT; ANTITHROMBINS; FACTOR VIIA; FIBRINOLYTIC AGENTS; HEPARIN; HUMANS; LIPOPROTEINS; MALE;

EID: 0034526718     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(00)00343-1     Document Type: Article

References (37)

1. Activation of factor IX by the reaction product of tissue factor and factor VII: Additional pathway for initiating blood coagulation
2. Altered factor VII activity in hemophilia
3. Initiation of the extrinsic pathway of blood coagulation: Evidence for the tissue factor dependent autoactivation of human coagulation factor VII
4. Deletion of the membrane anchoring region of tissue factor abolishes autoactivation of factor VII, but not cofactor function: Analysis of a mutant with selective deiciency in activity
5. Coagulation factor VII, dietary fat and blood lipids: A review
6. Haemostatic function and ischaemic heart disease: Principal results of the Northwick Park Heart Study
7. Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotic artery atherosclerosis
8. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation
9. A novel specific immunoassay for plasma two-chain factor VIIa: Investigation of FVIIa levels in normal individuals and in patients with acute coronary syndromes
10. Coagulation factor VII mass and activity in young men with myocardial infarction at a young age. Role of plasma lipoproteins and factor VII genotype
11. Fluorogenic assay of activated factor VII: Plasma factor VIIa levels in relation to arterial cardiovascular diseases in Japanese
12. Population correlates of coagulation factor VII: Importance of age, sex, and menopausal status as determinants of activated factor VII
13. Increased activation of the haemostatic system in men at high risk of fatal coronary heart disease
14. The lipoprotein-associated coagulation inhibitor that inhibits the factor VII-tissue factor complex also inhibits factor Xa: Insight into its possible mechanism of action
15. Modifications of extrinsic pathway inhibitor (EPI) and factor Xa that affect their ability to interact and to inhibit factor VIIa/tissue factor: Evidence for a two-step model of inhibition
16. Glycosaminoglycans and the regulation of blood coagulation
17. Heparin induces release of extrinsic coagulation pathway inhibitor (EPI)
18. Heparin lowers plasma levels of activated factor VII
19. Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa
20. Inhibition of factor VIIa/tissue factor by antithrombin III and tissue factor pathway inhibitor
21. Blocking of tissue factor pathway inhibitor (TFPI) shortens the bleeding time in rabbits with antibody induced haemophilia A
22. A more uniform measurement of factor VIII inhibitors
23. An enzyme linked immunosorption assay for tissue factor pathway inhibitor
24. Direct measurement of activated factor VII in plasma: Development of an original assay
25. Complex-dependent inhibition of factor VIIa by antithrombin III and heparin
26. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
27. Inhibition of extrinsic pathway shortens the coagulation time of normal plasma and of hemophilic plasma
28. Extrinsic pathway inhibitor (EPI) released to the blood by heparin is a more powerful coagulation inhibitor than is recombinant EPI
29. The effect of heparin and its neutralisation on functional assays for factor VIIa, factor VII and TFPI
30. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin
31. Suppression of plasma-activated factor VII levels by Warfarin therapy
32. Effects of total fat content and fatty acid composition in diet on factor VII coagulant activity and blood lipids
33. Strenuous exercise, plasma fibrinogen, and factor VII activity
34. Sustained improvement in blood lipids, coagulation, and fibrinolysis after major weight loss in obese subjects
35. Decrease in factor VII coagulant activity during percutaneous transluminal coronary angioplasty by heparin-mediated lipolytic action
36. The tissue factor pathway how it has become a "prima ballerina"